Bolt Biotherapeutics Q3 2025: operating loss $7.7M, cash $38.8M; BDC-4182 data expected 3Q26

Bolt Biotherapeutics, Inc.

2025-Q3 EPS reported -$13.94 vs consensus -$5.90 ▼ miss (-136.1%)

Collaboration revenue $2.2M (vs $1.1M Q3 2024); R&D expenses $6.5M (down 53% YoY).
Operating loss $7.7M vs $16.4M YoY, reflecting restructuring and discontinuation of BDC-1001.
Cash and securities $38.8M as of Sep 30, 2025; runway into 2027.
Initial Phase 1 data for BDC-4182 (claudin 18.2 ISAC) expected 3Q2026.
Presented preclinical data for next-gen CEA and PD-L1 ISACs at SITC; seeking partner for BDC-3042.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.